ABBOTT LABORATORIES Deferred Revenue Recognized
ABBOTT LABORATORIES (ABT) reported Deferred Revenue Recognized of $123.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-04-29
- ABBOTT LABORATORIES contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $123.00M, a 24.24% increase year-over-year.
- ABBOTT LABORATORIES contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $99.00M, a 14.66% decline year-over-year.
- ABBOTT LABORATORIES contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $116.00M.
- ABBOTT LABORATORIES contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was -$93.00M.
- ABBOTT LABORATORIES contract with customer, liability, revenue recognized for fiscal 2025 was -$423.00M.
- ABBOTT LABORATORIES contract with customer, liability, revenue recognized for fiscal 2024 was -$460.00M.
- ABBOTT LABORATORIES contract with customer, liability, revenue recognized for fiscal 2023 was -$424.00M.
- ABBOTT LABORATORIES contract with customer, liability, revenue recognized for fiscal 2022 was -$598.00M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-03-31 | $123.00M 10-Q · filed 2026-04-29 | |||
| 2025-12-31 | -$423.00M 10-K · filed 2026-02-20 | |||
| 2025-09-30 | $300.00M 10-Q · filed 2025-10-29 | |||
| 2025-06-30 | $192.00M 10-Q · filed 2025-07-30 | |||
| 2025-03-31 | $99.00M 10-Q · filed 2025-04-30 | |||
| 2024-12-31 | -$460.00M 10-K · filed 2026-02-20 | |||
| 2024-09-30 | $329.00M 10-Q · filed 2024-10-31 | |||
| 2024-06-30 | $233.00M 10-Q · filed 2024-07-31 | |||
| 2024-03-31 | $116.00M 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | -$424.00M 10-K · filed 2025-02-21 | |||
| 2023-09-30 | $292.00M 10-Q · filed 2023-11-01 | |||
| 2023-06-30 | $192.00M 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | -$93.00M 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | -$598.00M 10-K · filed 2024-02-16 | |||
| 2022-09-30 | $508.00M 10-Q · filed 2022-11-01 | |||
| 2022-06-30 | $324.00M 10-Q · filed 2022-08-02 | |||
| 2022-03-31 | -$178.00M 10-Q · filed 2022-05-03 | |||
| 2021-12-31 | -$500.00M 10-K · filed 2023-02-17 | |||
| 2021-09-30 | -$409.00M 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | -$279.00M 10-Q · filed 2021-08-04 | |||
| 2021-03-31 | -$163.00M 10-Q · filed 2021-05-05 | |||
| 2020-12-31 | -$394.00M 10-K · filed 2022-02-18 | |||
| 2020-09-30 | -$293.00M 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | -$192.00M 10-Q · filed 2020-07-29 | |||
| 2020-03-31 | -$94.00M 10-Q · filed 2020-04-29 | |||
| 2019-12-31 | -$376.00M 10-K · filed 2021-02-19 | |||
| 2019-09-30 | -$249.00M 10-Q · filed 2019-10-31 | |||
| 2019-06-30 | -$163.00M 10-Q · filed 2019-07-31 | |||
| 2019-03-31 | -$86.00M 10-Q · filed 2019-05-01 | |||
| 2018-12-31 | -$243.00M 10-K · filed 2020-02-21 | |||
| 2018-09-30 | -$155.00M 10-Q · filed 2018-10-31 | |||
| 2018-06-30 | -$103.00M 10-Q · filed 2018-08-01 | |||
| 2018-03-31 | -$43.00M 10-Q · filed 2018-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |